New triple therapy aims to tame tough diabetes
NCT ID NCT06290349
First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests whether adding a third medication (DA5221-T) to an existing two-drug combination can improve blood sugar control in adults with type 2 diabetes. About 174 participants who still have high blood sugar despite taking two diabetes drugs will receive either the extra drug or a placebo for 24 weeks. The main goal is to see if the triple therapy lowers HbA1c (a measure of average blood sugar) more effectively than the two-drug regimen alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Severance Hospital, Yonsei University college of Medicine
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.